Research Focused on the Adalimumab Market Forecast Up to 2024
Adalimumab, with a trade name of Humira and Exemptia, is an anti-TNF drug used for treating rheumatoid arthritis, psoriatic arthritis, Crohn's disease, psoriasis and ulcerative colitis. Adalimumab usually binds with tumor necrosis factor-alpha (TNF?). When a TNF? binds to a TBF? receptors, it results in an inflammatory response to autoimmune disease. Adalimumab, by binding to a TNF?, lowers the chances of inflammatory response.
View full press release